Medicenna Therapeutics to present as NBTS Research Roundtable

Medicenna Therapeutics announced that Dr. Fahar Merchant, the Company’s President and CEO, was invited to participate and present at the Research Roundtable organized by the National Brain Tumor Society, NBTS. The event, titled “Use of External Control Data in Brain Tumor Clinical Trials” took place on July 20, 2023, in Washington, D.C. “Medicenna has been recognized for its innovative work in the treatment of rGBM, a uniformly fatal form of brain cancer. Compelling results from the Company’s MDNA55 Phase 2b trial were recently published in the journal Neuro-Oncology, and when compared to a well-matched external control, bizaxofusp more than doubled the median survival in end-stage rGBM patients”, said Dr. Merchant. “It was a privilege to share our pioneering efforts of leveraging data from patient registries together with promising Phase 2b results that secured Medicenna a precedent-setting FDA nod for the first-ever Phase 3 trial in rGBM using an external control arm. We believe that working alongside NBTS, together with experts from leading U.S. hospitals and pharma companies who share our vision to harness the power of external control data, may enhance the efficiency of clinical research and enable faster access to novel therapies for GBM” added Dr. Merchant.